| Idiopathic Pulmonary Fibrosis
Rayos vs Ofev
Side-by-side clinical, coverage, and cost comparison for idiopathic pulmonary fibrosis.Deep comparison between: Rayos vs Ofev with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOfev has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ofev but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Ofev
At A Glance
Oral
Daily
Corticosteroid
Oral
Twice daily
Kinase inhibitor
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Idiopathic Pulmonary Fibrosis
- PF-ILD-progressive fibrosing interstitial lung disease
- Lung disease with systemic sclerosis
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Idiopathic Pulmonary Fibrosis, PF-ILD-progressive fibrosing interstitial lung disease, Lung disease with systemic sclerosis 150 mg orally twice daily approximately 12 hours apart with food; reduce to 100 mg twice daily in mild hepatic impairment (Child Pugh A).
Contraindications
- Known hypersensitivity to prednisone or any excipient
—
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Most common (>=5%) Diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased, hypertension
Serious Bronchitis, myocardial infarction, pneumonia, elevated liver enzymes, gastrointestinal disorders, arterial thromboembolic events, bleeding, gastrointestinal perforation
Postmarketing Thrombocytopenia, pancreatitis, drug-induced liver injury, posterior reversible encephalopathy syndrome, proteinuria, pruritus, rash, bleeding events
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Nintedanib is a small-molecule inhibitor of multiple receptor tyrosine kinases (PDGFR alpha/beta, FGFR 1-3, VEGFR 1-3, CSF1R, FLT-3) and non-receptor tyrosine kinases (Lck, Lyn, Src), blocking intracellular signaling cascades involved in fibrotic tissue remodeling in interstitial lung disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Ofev
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ofev
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Ofev
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
Cost estimate not availableAccessia Health: Pulmonary Fibrosis - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.